Literature DB >> 30853453

MicroRNA-34a Promotes Renal Fibrosis by Downregulation of Klotho in Tubular Epithelial Cells.

Yong Liu1, Xianjin Bi1, Jiachuan Xiong1, Wenhao Han1, Tangli Xiao1, Xinli Xu1, Ke Yang1, Chi Liu1, Wei Jiang1, Ting He1, Yanlin Yu1, Yan Li1, Jingbo Zhang1, Bo Zhang1, Jinghong Zhao2.   

Abstract

Renal fibrosis is the main pathological characteristic of chronic kidney disease (CKD), whereas the underlying mechanisms of renal fibrosis are not clear yet. Herein, we found an increased expression of microRNA-34a (miR-34a) in renal tubular epithelial cells of patients with renal fibrosis and mice undergoing unilateral ureteral obstruction (UUO). In miR-34a-/- mice, miR-34a deficiency attenuated the progression of renal fibrosis following UUO surgery. The miR-34a overexpression promoted epithelial-to-mesenchymal transition (EMT) in cultured human renal tubular epithelial HK-2 cells, which was accompanied by sharp downregulation of Klotho, an endogenous inhibitor of renal fibrosis. Luciferase reporter assay revealed that miR-34a downregulated Klotho expression though direct binding with the 3' UTR of Klotho. Conversely, overexpression of Klotho prevented miR-34a-induced EMT in HK-2 cells. Furthermore, results showed that miR-34a was induced by transforming growth factor β1 (TGF-β1) through p53 activation, whereas dihydromyricetin could inhibit TGF-β1-induced miR-34a overexpression. Accordingly, dihydromyricetin administration dramatically restored the aberrant upregulation of miR-34a and Klotho reduction in obstructed kidney, and markedly ameliorated renal fibrosis in the Adriamycin nephropathy and UUO model mice. These findings suggested that miR-34a plays an important role in the progression of renal fibrosis, which provides new insights into the pathogenesis and treatment of CKD.
Copyright © 2019 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Klotho; TGF-β1; dihydromyricetin; microRNA-34a; renal fibrosis

Mesh:

Substances:

Year:  2019        PMID: 30853453      PMCID: PMC6520492          DOI: 10.1016/j.ymthe.2019.02.009

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  62 in total

1.  Targeted deletion of p53 in the proximal tubule prevents ischemic renal injury.

Authors:  Yuan Ying; Jinu Kim; Sherry N Westphal; Kelly E Long; Babu J Padanilam
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

2.  p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.

Authors:  Liz J Valente; Daniel H D Gray; Ewa M Michalak; Josefina Pinon-Hofbauer; Alex Egle; Clare L Scott; Ana Janic; Andreas Strasser
Journal:  Cell Rep       Date:  2013-05-09       Impact factor: 9.423

3.  Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality.

Authors:  Hicham I Cheikh Hassan; Mila Tang; Ognjenka Djurdjev; David Langsford; Manish M Sood; Adeera Levin
Journal:  Kidney Int       Date:  2016-08-31       Impact factor: 10.612

4.  Redox control of p53 in the transcriptional regulation of TGF-β1 target genes through SMAD cooperativity.

Authors:  Jessica M Overstreet; Rohan Samarakoon; Kirstan K Meldrum; Paul J Higgins
Journal:  Cell Signal       Date:  2014-03-05       Impact factor: 4.315

5.  Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis.

Authors:  Bo Wang; Radko Komers; Rosemarie Carew; Catherine E Winbanks; Bei Xu; Michal Herman-Edelstein; Philip Koh; Merlin Thomas; Karin Jandeleit-Dahm; Paul Gregorevic; Mark E Cooper; Phillip Kantharidis
Journal:  J Am Soc Nephrol       Date:  2011-11-17       Impact factor: 10.121

6.  Prevalence of chronic kidney disease in the United States.

Authors:  Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey
Journal:  JAMA       Date:  2007-11-07       Impact factor: 56.272

7.  Reactive oxygen species/oxidative stress contributes to progression of kidney fibrosis following transient ischemic injury in mice.

Authors:  Jinu Kim; Young Mi Seok; Kyong-Jin Jung; Kwon Moo Park
Journal:  Am J Physiol Renal Physiol       Date:  2009-05-20

8.  Protective Effect of Dihydromyricetin Against Lipopolysaccharide-Induced Acute Kidney Injury in a Rat Model.

Authors:  Jun-Tao Wang; Peng Jiao; Yun Zhou; Qian Liu
Journal:  Med Sci Monit       Date:  2016-02-11

9.  MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy.

Authors:  Cristina Zanchi; Daniela Macconi; Piera Trionfini; Susanna Tomasoni; Daniela Rottoli; Monica Locatelli; Michael Rudnicki; Jo Vandesompele; Pieter Mestdagh; Giuseppe Remuzzi; Ariela Benigni; Carlamaria Zoja
Journal:  Diabetologia       Date:  2017-03-31       Impact factor: 10.122

10.  Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice.

Authors:  Bin Wu; Jie Lin; Jian Luo; Dong Han; Miaomiao Fan; Tao Guo; Ling Tao; Ming Yuan; Fu Yi
Journal:  Biomed Res Int       Date:  2017-03-21       Impact factor: 3.411

View more
  40 in total

Review 1.  Connecting sex differences, estrogen signaling, and microRNAs in cardiac fibrosis.

Authors:  Lejla Medzikovic; Laila Aryan; Mansoureh Eghbali
Journal:  J Mol Med (Berl)       Date:  2019-08-26       Impact factor: 4.599

Review 2.  Emerging role of tumor suppressor p53 in acute and chronic kidney diseases.

Authors:  Jessica M Overstreet; Cody C Gifford; Jiaqi Tang; Paul J Higgins; Rohan Samarakoon
Journal:  Cell Mol Life Sci       Date:  2022-08-09       Impact factor: 9.207

Review 3.  Epigenetics in kidney diseases.

Authors:  Hao Ding; Lu Zhang; Qian Yang; Xiaoqin Zhang; Xiaogang Li
Journal:  Adv Clin Chem       Date:  2020-10-21       Impact factor: 6.303

Review 4.  The Role of MicroRNA in the Regulation of Tumor Epithelial-Mesenchymal Transition.

Authors:  Jing Feng; Shaofan Hu; Keli Liu; Guiyin Sun; Yiguo Zhang
Journal:  Cells       Date:  2022-06-21       Impact factor: 7.666

Review 5.  MicroRNA-34a: A Novel Therapeutic Target in Fibrosis.

Authors:  Min Zhao; Qin Qi; Shimin Liu; Rong Huang; Jiacheng Shen; Yi Zhu; Jing Chai; Handan Zheng; Huangan Wu; Huirong Liu
Journal:  Front Physiol       Date:  2022-06-20       Impact factor: 4.755

Review 6.  Epigenetic modifications of Klotho expression in kidney diseases.

Authors:  Jinkun Xia; Wangsen Cao
Journal:  J Mol Med (Berl)       Date:  2021-02-06       Impact factor: 4.599

Review 7.  The Protective Role of Klotho in CKD-Associated Cardiovascular Disease.

Authors:  Xianjin Bi; Ke Yang; Bo Zhang; Jinghong Zhao
Journal:  Kidney Dis (Basel)       Date:  2020-08-19

8.  Klotho is regulated by transcription factor Sp1 in renal tubular epithelial cells.

Authors:  Yan Li; Yong Liu; Kailong Wang; Yinghui Huang; Wenhao Han; Jiachuan Xiong; Ke Yang; Mingying Liu; Tangli Xiao; Chi Liu; Ting He; Xianjin Bi; Jingbo Zhang; Bo Zhang; Jinghong Zhao
Journal:  BMC Mol Cell Biol       Date:  2020-06-22

9.  PAI-1 induction during kidney injury promotes fibrotic epithelial dysfunction via deregulation of klotho, p53, and TGF-β1-receptor signaling.

Authors:  Cody C Gifford; Fei Lian; Jiaqi Tang; Angelica Costello; Roel Goldschmeding; Rohan Samarakoon; Paul J Higgins
Journal:  FASEB J       Date:  2021-07       Impact factor: 5.191

Review 10.  The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury.

Authors:  Li Ning; Xiong Rui; Wang Bo; Geng Qing
Journal:  Cell Death Dis       Date:  2021-07-23       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.